Dr. Sato

Takami Sato, MD, PhD

Contact Dr. Sato

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Phase i Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients with Metastatic Uveal Melanoma
  2. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
  3. Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs
  4. A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma
  5. First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer
  6. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
  7. Checkpoint inhibitor immune therapy
  8. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer
  9. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment
  10. Immune check point inhibitors combination in melanoma: Worth the toxicity?
  11. Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T)
  12. Successes and setbacks of early investigational drugs for melanoma
  13. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity
  14. High-dose vincristine sulfate liposome injection (Marqibo) is not associated with clinically meaningful hematologic toxicity
  15. Early arterial stasis during resin-based yttrium-90 radioembolization: Incidence and preliminary outcomes
  16. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
  17. Uveal melanoma trapped in the temple of doom
  18. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma
  19. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy
  20. Toxicities after radioembolization with yttrium-90 SIR-spheres: Incidence and contributing risk factors at a single center
  21. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: A pilot study
  22. Side-branch embolization before90Y radioembolization: Rate of recanalization and new collateral development
  23. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine
  24. Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: are there safe and potentially effective treatments?
  25. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma